The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.

Primary objective To investigate treatment response to NEXIUM in patients with reflux esophagitis (RE).

Secondary objectives

To investigate following items in patients with RE:

1. Patient satisfactory level of the treatment for RE
2. Health-related quality of life (HRQOL)
3. Severity and frequency of RE symptoms reported by physicians
4. Endoscopic healing rate
5. Development of ADRs

Inclusion Criteria:

• Patients to be enrolled in this S-CEI must fulfill all the criteria below at the start of the treatment with NEXIUM.

  1. Aged at least 20 years.
  2. Patients who has a current or past history of clinically diagnosed RE
  3. Patients whose answers in the baseline GerdQ include "2-3 days" or "4-7 days" in at least one of the questions Nos 1, 2, 5 and 6.
  4. Patients to whom NEXIUM 20 mg once daily is to be administered for RE
  5. Patients from whom written consent has been obtained.

Exclusion Criteria:

• Patients must not enter the investigation if any of the following exclusion criteria are fulfilled at the start of the treatment with NEXIUM:

  1. Patients whose ability to follow instructions are suspected to be low by physicians
  2. Patients with a past history of hypersensitivity to the ingredients of NEXIUM.
  3. Patients receiving atazanavir sulfate or rilpivirine hydrochloride
  4. Patients who have received NEXIUM within the past eight weeks for treatment of RE

Since the target patient population of the S-CEI is symptomatic RE patients, the patients fulfilling the inclusion criteria and not the exclusion criteria shown below will be enrolled as the subjects of this investigation.